tbuckley/cabot-search huggingface dataset:
TCT-80 Characterizing the Incidence and Predictors of Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement (TAVR) and its Impact on Outcomes: A Study of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies (STS/ACC TVT) Registry
Authors: Saif Anwaruddin, Ajay Kirtane, Vinod Thourani, Sreekanth Vemulapalli, Pratik Manandhar, Nimesh Desai, Howard Herrmann, Joseph Bavaria, Jay Giri, Prashanth Vallabhajosyula, Wilson Y. Szeto
Journal: Journal of the American College of Cardiology (2016)
In Vitro analysis of Suicide Gene Expression and Function of 3 Suicide Gene-Prodrug Combinations In Human T Lymphocytes Further Modified to Express the CD19 Targeted 19–28z Chimeric Antigen Receptor.
Authors: Jae H. Park, Raymond Yeh, Isabelle Rivière, Michel Sadelain, Renier J. Brentjens
Journal: Blood (2010)
TCT-357 Impact of Gender and Age on 3-Year Clinical Outcome and Chest Pain of Patients With Coronary Artery Disease Treated With Contemporary Drug-Eluting Stents: A Patient-Level Pooled Analysis
Authors: Marlies Kok, Liefke van der Heijden, Marije Lowik, Paolo Zocca, Carine J.M. Doggen, Peter Danse, Rutger L. Anthonio, Marc Hartmann, Gerard C.M. Linssen, Angela Maas, Roxana Mehran, Clemens von Birgelen
Journal: Journal of the American College of Cardiology (2016)
TCT-671 The Role of Pre-existing Aortic Regurgitation on The Clinical Impact of Aortic Regurgitation after Transcatheter Aortic Valve Implantation
Authors: Hiroki Tateishi, Mohammad Abdelghani, Rafael Cavalcante, Yosuke Miyazaki, Carlos Campos, Carlos Collet, Tristan Slots, Rogerio Sarmento-Leite, Jose Mangione, Alexandre Abizaid, Osama Soliman, Ernest Spitzer, Yoshinobu Onuma, Patrick Serruys, Pedro Lemos, Fabio Brito
Journal: Journal of the American College of Cardiology (2016)
TERAPIA INCISIONAL EN PACIENTES CON ESTENOSIS ESOFÁGICA POSTQUIRÚRGICA
Authors: AD Polanco Jimenez, A Lopez Serrano, CA Amurrio Gonzalez, A Pascual Romero, MJ Suarez Davalos, I Ortiz Polo, P Latorre Año, C Garcia Orts, J Hervas Martin, E Moreno Osset
Journal: Endoscopy (2016)

Introducción: La estenosis esofágica postquirúrgica (EEP) es una complicación frecuente. El tratamiento endoscópico mediante dilatación neumática presenta alta tasa de recurrencia, requiriendo repetidas sesiones. La Terapia Incisional con Incisión Radial y Corte (TI) se ha postulado como una posible alternativa en esta situación.
Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial
Authors: Istvan Majer, Arun Krishna, Gijs van de Wetering, Jesús F. San-Miguel, Paul G. Richardson
Journal: Blood (2015)
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
Authors: Anuradha Tarafdar, Lisa E. M. Hopcroft, Paolo Gallipoli, Francesca Pellicano, Jennifer Cassels, Alan Hair, Koorosh Korfi, Heather G. Jørgensen, David Vetrie, Tessa L. Holyoake, Alison M. Michie
Journal: Blood (2016)
A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis
Authors: Puneeta Tandon, K. Rajender Reddy, Jacqueline G. O'Leary, Guadalupe Garcia‐Tsao, Juan G. Abraldes, Florence Wong, Scott W. Biggins, Benedict Maliakkal, Michael B. Fallon, Ram M. Subramanian, Paul Thuluvath, Patrick S. Kamath, Leroy R. Thacker, Jasmohan S. Bajaj
Journal: Hepatology (2016)

Identification of patients with cirrhosis at risk for death within 3 months of discharge from the hospital is essential to individualize postdischarge plans. The objective of the study was to identify an easy-to-use prognostic model based on the Karnofsky Performance Status (KPS). The North American Consortium for the Study of End-Stage Liver Disease consists of 16 tertiary-care hepatology centers that prospectively enroll nonelectively admitted cirrhosis patients. Patients enrolled had KPS assessed 1 week postdischarge. KPS was categorized into low (score 10-40), intermediate (50-70), and high (80-100). Of 954 middle-aged patients (57 ± 10 years, 63% men) with a median Model for End-Stage Liver Disease (MELD) score of 17 (interquartile range 13-21), the mortality rates for the low, intermediate, and high performance status groups were 23% (36/159), 11% (55/489), and 5% (15/306), respectively. Low, intermediate, and high performance status was seen in 17%, 51%, and 32% of the cohort, respectively. Low performance status was associated with older age, dialysis, hepatic encephalopathy, longer length of stay, and higher white blood cell count or MELD score at discharge. A model was derived using the three independent predictors of 3-month mortality: KPS, age, and MELD score. This score had better discrimination (area under the receiver operating characteristic curve = 0.74) than a model using MELD (area under the receiver operating characteristic curve = 0.62) or MELD and age (area under the receiver operating characteristic curve = 0.67) to predict 3-month mortality. Conclusions: Cirrhosis patients at risk for 3-month postdischarge mortality can be identified using a novel KPS-based score; this score may be adopted in practice to guide postdischarge early interventions, including the integrated provision of active and palliative management strategies. (Hepatology 2017;65:217-224).
The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph−) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.
Authors: Isabel Granada, Juan-Manuel Sancho, Albert Oriol, Mireia Morgades, Concepción Bethencourt, Ricardo Parody, Jesús-María Hernández-Rivas, Maria-José Moreno, Eloy Del-Potro, Mar Tormo, Concepción Rivas, Miguel-Angel Sanz, Carlos Grande, Javier Bueno, Eugenia Abella, Juan-José Ortega, Josep-Maria Ribera
Journal: Blood (2007)
Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine
Authors: Gao-Na Shi, Chuang-Nian Zhang, Rong Xu, Jin-Feng Niu, Hui-Juan Song, Xiu-Yuan Zhang, Wei-Wei Wang, Yan-Ming Wang, Chen Li, Xiao-Qing Wei, De-Ling Kong
Journal: Biomaterials (2016)
TCT-689 Tailored Therapy in TAVI: Outcomes of a Device Selection Algorithm based on the Presence of Risk Factors for Paravalvular Regurgitation
Authors: Ayoub El Hammiri, Zied Frikha, Charbel Naim, Jeannot Potvin, Francois Gobeil, Louis-Mathieux Stevens, Nicolas Noiseux, Jean-Bernard Masson
Journal: Journal of the American College of Cardiology (2016)
Clinical Outcomes for Patients with Severe Chronic Neutropenia Due to Mutations in the Gene for Neutrophil Elastase, ELANE
Authors: Vahagn Makaryan, Cornelia Zeidler, Audrey Anna Bolyard, Julia Skokowa, Merideth L. Kelley, Laurence A. Boxer, Mary Ann Bonilla, Peter E. Newburger, Akiko Shimamura, Karl Welte, David C. Dale
Journal: Blood (2012)
P0404 : Cyclin E1 expression level determine the anti-proliferative response of the pharmacological Cdk2 inhibitor roscovitine in hepatoma cells and liver
Authors: Y.A. Nevzorova, W. Hu, N. Hoeltke, U. Haas, C. Trautwein, C. Liedtke
Journal: Journal of Hepatology (2015)
ENTEROSCOPIA MONOBALON CON SEDACION PROFUNDA CONTROLADA POR NO ANESTESISTA
Authors: A López Baz, D Tardáguila García, A Fernández López, B Alvarez Suárez, A Dacal Rivas, E Martí Marqués, A González Ramírez, L López Rosés
Journal: Endoscopy (2016)

Introducción: La enteroscopia es un procedimiento habitualmente realizado bajo sedación o anestesia general, controlada por anestesista.
TCT-521 Novel non-invasive quantitative flow ratio for estimating fractional flow reserve
Authors: Antoinette Neylon, Andrew Roy, Thomas Hovasse, Bernard Chevalier, Philippe Garot, Hakim Benamer, Yves Louvard, Leticia Fernandez-Lopez, Fadi Sawaya, Marco Spaziano, Yann Roux, Thierry Lefevre
Journal: Journal of the American College of Cardiology (2016)
TCT-586 Utility of intracoronary imaging techniques in the characterisation of substrates causing acute coronary syndrome in normal o near normal coronary angiography (NONCA)
Authors: Santiago Jesús Camacho Freire, Antonio Gomez Menchero, Javier Leon Jimenez, Rosamariacardenal Piris, Jessica Roa-Garrido, jose morgado, Prudenciagomez Fernandez, Francisco Javier Landero Garcia, J.F. Diaz Fernandez
Journal: Journal of the American College of Cardiology (2016)
TCT-411 Risk and timing of clinical events according to diabetic status of patients treated with Everolimus-Eluting Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting stent: 2-Year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials
Authors: Carlos Campos, Alexandre Abizaid, Adriano Caixeta, Antonio Bartorelli, Robert Whitbourn, Marco Perin
Journal: Journal of the American College of Cardiology (2016)
Collaboration Between MiR-125b, MiR-100 and MiR-99a Induces Vincristine Resistance in Childhood TEL-AML1-Positive Acute Lymphoblastic Leukemia
Authors: Farhad Akbari Moqadam, Ellen Lange-Turenhout, Rob Pieters, Monique L. Den Boer
Journal: Blood (2012)
A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants
Authors: Brian S White, Irena Lanc, Daniel Auclair, Robert Fulton, Mark A Fiala, Justin King, Gregory Ahmann, Mary Derome, Elaine R Mardis, Joan Levy, Ravi Vij, John F. DiPersio, Michael Tomasson
Journal: Blood (2015)
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
Authors: C.E.M. Griffiths, D. Thaçi, S. Gerdes, P. Arenberger, G. Pulka, K. Kingo, J. Weglowska, N. Hattebuhr, J. Poetzl, H. Woehling, G. Wuerth, M. Afonso
Journal: British Journal of Dermatology (2017)

Summary Background GP2015 is a proposed etanercept biosimilar. Objectives To demonstrate equivalent efficacy, and comparable safety and immunogenicity of GP2015 and the etanercept originator (ETN, Enbrel®) in patients with moderate-to-severe chronic plaque-type psoriasis. Methods In total, 531 eligible patients were randomized 1 : 1 to self-administer GP2015 or ETN twice weekly subcutaneously. Patients with ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were rerandomized to continue the same treatment on a once-weekly dosing schedule or to undergo a sequence of three treatment switches between GP2015 and ETN until week 30. Thereafter, patients continued treatment with the product they had been assigned to last, up to week 52. Results The difference in PASI 75 (75% improvement from baseline PASI score) response rates at week 12 between GP2015 and ETN (primary end point) was −2·3%. The 95% confidence interval (−9·85 to 5·30) was well contained within the prespecified margin range of −18 to 18. The incidence of treatment-emergent adverse events up to week 52 was comparable between continued GP2015 (59·8%) and ETN (57·3%); switching treatments revealed comparable safety profiles. Antidrug antibodies, all non-neutralizing, were limited to five patients on ETN during treatment period 1, and one patient in the switched ETN group, who had been treated with GP2015 for 12 weeks at the time of the finding. Conclusions The EGALITY study demonstrated equivalent efficacy and comparable safety and immunogenicity of GP2015 and ETN. The study results provide the final clinical confirmation of biosimilarity and contribute to the totality of the evidence proposing that GP2015 is an etanercept biosimilar.
TCT-96 Progression of coronary atherosclerosis despite lipid-lowering therapy in diabetic patients compared to non-dibetic ones. Study with 3D intravascular ultrasound and virtual histology
Authors: Tomas Kovarnik, Zhi Chen, Andreas Wahle, Ales Kral, Martin Chval, Karel Kopriva, John Lopez, Milan Sonka, Ales Linhart
Journal: Journal of the American College of Cardiology (2016)
Technological considerations for genome-guided diagnosis and management of cancer
Authors: Niall J. Lennon, Viktor A. Adalsteinsson, Stacey B. Gabriel
Journal: Genome Medicine (2016)

Technological, methodological, and analytical advances continue to improve the resolution of our view into the cancer genome, even as we discover ways to carry out analyses at greater distances from the primary tumor sites. These advances are finally making the integration of cancer genomic profiling into clinical practice feasible. Formalin fixation and paraffin embedding, which has long been the default pathological biopsy medium, is now being supplemented with liquid biopsy as a means to profile the cancer genomes of patients. At each stage of the genomic data generation process—sample collection, preservation, storage, extraction, library construction, sequencing, and variant calling—there are variables that impact the sensitivity and specificity of the analytical result and the clinical utility of the test. These variables include sample degradation, low yields of nucleic acid, and low variant allele fractions (proportions of assayed molecules carrying variant allele(s)). We review here the most common pre-analytical and analytical factors relating to routine cancer patient genome profiling, some solutions to common challenges, and the major sample preparation and sequencing technology choices available today.
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
Authors: Rafael Bejar, Elli Papaemmanuil, Torsten Haferlach, Guillermo Garcia-Manero, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Matthew J. Walter, Timothy A. Graubert, Mario Cazzola, Luca Malcovati, Seishi Ogawa, Pierre Fenaux, Eva Hellstrom-Lindberg, Wolfgang Kern, Jacqueline Boultwood, Andrea Pellagatti, David Bowen, Sudhir Tauro, Michael J Groves, Paresh Vyas, Lynn Quek, Aziz Nazha, Felicitas Thol, Michael Heuser, Lee-Yung Shih, Eric Padron, David Sallman, Rami S. Komrokji, Alan F. List, Valeria Santini, Michaela Fontenay, Peter J Campbell, Heinz Tüchler, Kristen Stevenson, Donna S Neuberg, Peter Greenberg, Benjamin L Ebert
Journal: Blood (2015)
Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty
Authors: Vincent Cottin
Journal: European Respiratory Journal (2016)

The efficacy and approval of two antifibrotic drugs [1, 2], the increased mortality of idiopathic pulmonary fibrosis (IPF) from corticosteroids and anticoagulants [3, 4], and the availability of data from multiple drug trials have tremendously increased the need for an accurate diagnosis of interstitial lung disease (ILD). As stated in international guidelines [5], in the appropriate clinical setting with all possible causes of ILD ruled out, the presence of a definite usual interstitial pneumonia (UIP) pattern on chest computed tomography (CT) is sufficient for the diagnosis of IPF. In the absence of a UIP pattern on CT, establishing a secure diagnosis of IPF requires a surgical lung biopsy [5]. This approach, therefore, relies heavily on the CT appearance of ILD that is stratified into three categories, namely UIP, possible UIP and inconsistent with UIP. In theory, a lung biopsy should be contemplated in patients with a pattern of possible UIP or inconsistent with UIP. All possibly relevant information available is then synthesised during the multidisciplinary discussion among clinicians, radiologists and pathologists, all being experts in the field of ILD, a process that increases the accuracy of the diagnosis [6] and impacts management [7]. The multidisciplinary discussion also allows the diagnosis to be made with higher confidence than by clinicians or radiologists alone (although reproducibility between different teams needs to be optimised for diagnoses other than IPF [8]), and has become the gold standard for the diagnosis of ILD. Diagnostic guidelines now need to be amended to better correspond to the pragmatic management of ILD <http://ow.ly/97M8304aylG>
Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: A Scientific Statement From the American Heart Association
Authors: Linda Van Horn, Jo Ann S. Carson, Lawrence J. Appel, Lora E. Burke, Christina Economos, Wahida Karmally, Kristie Lancaster, Alice H. Lichtenstein, Rachel K. Johnson, Randal J. Thomas, Miriam Vos, Judith Wylie-Rosett, Penny Kris-Etherton
Journal: Circulation (2016)

In 2013, the American Heart Association and American College of Cardiology published the "Guideline on Lifestyle Management to Reduce Cardiovascular Risk," which was based on a systematic review originally initiated by the National Heart, Lung, and Blood Institute. The guideline supports the American Heart Association's 2020 Strategic Impact Goals for cardiovascular health promotion and disease reduction by providing more specific details for adopting evidence-based diet and lifestyle behaviors to achieve those goals. In addition, the 2015-2020 Dietary Guidelines for Americans issued updated evidence relevant to reducing cardiovascular risk and provided additional recommendations for adopting healthy diet and lifestyle approaches. This scientific statement, intended for healthcare providers, summarizes relevant scientific and translational evidence and offers practical tips, tools, and dietary approaches to help patients/clients adapt these guidelines according to their sociocultural, economic, and taste preferences.
EFICACIA Y SEGURIDAD DEL MANEJO ENDOSCÓPICO DE LOS PÓLIPOS COLÓNICOS NO PEDICULADOS MAYORES DE 2 CM EN UN HOSPITAL DE TERCER NIVEL
Authors: M San Juan, I Redondo, M Muñoz, D García, A Amorós, P Borque, P Bennemann, L Navazo, X Arguiñarena, S Morales
Journal: Endoscopy (2016)

Introduccion: Los pólipos colónicos ≥2 cm se asocian a mayor riesgo de malignización, manejo endoscópico más complejo y aumento de complicaciones, requiriendo en algunos casos tratamiento quirúrgico.
TCT-717 Transcatheter Aortic Valve Replacement Reduces Major Recurrent Gastrointestinal Bleed in Severe Aortic Stenosis
Authors: Rafath Ullah, Mubeen Khan Mohammed Abdul, Khalil Odeh, Tanvir Bajwa, Suhail Q. Allaqaband, Amanda Kirby, Daniel P. O'Hair, Tonga Nfor
Journal: Journal of the American College of Cardiology (2016)
Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
Authors: E. Vasile, S. Caponi, M. Lucchesi, M. Del Chiaro, N. Funel, L. Ginocchi, D. Campani, A. Falcone, U. Boggi, F. Mosca
Journal: Journal of Clinical Oncology (2010)

e14605 Background: The natural history of invasive carcinomas derived from IPMNs is not well defined; few data on prognostic factors have been reported and the role for adjuvant treatment is not still clear. Methods: In order to evaluate the prognostic role of clinical and pathological factors (sex, age, number of positive and resected nodes, tumor staging, grading, adjuvant treatment), we performed a retrospective analysis on 43 patients who underwent a radical surgical resection for an invasive IPMNs at our institutions from 3/2004 to 3/2009. Results: Thirty-nine (M/F 20/19) were considered eligible (4 patients were excluded for postoperative deaths or incomplete follow up). Median age was 67 years (range 37-87). Most patients (31, 79%) had T3 tumor and 21 (54%) had positive nodes. Eighteen (46%) patients received gemcitabine-based adjuvant chemotherapy; fourteen of these had positive nodes and 7 have been also treated with radiotherapy. After a median follow up of 32 months, 20 patients progressed and 11 died; the site of first progression was: lung in 6 cases, liver in 5, peritoneum and local recurrence in 3 cases each, other or multiple site in 3 cases. The estimated median disease-free survival (DFS) was 28.6 months; median overall survival (OS) was not still reached (NR). Lymph node involvement (N1) resulted the main prognostic factor in univariate analysis (DFS 12.8 vs. 44.2 months, p = 0.01, and OS 23 months vs. NR, p = 0.03, for N1 vs. N0 patients). Other prognostic factors were: T parameter (DFS 16.7 months vs NR for T3 vs. T1-2; p = 0.04) and adjuvant chemotherapy for N1 patients (DFS 10.5 vs. 16.5 months, p = 0.05, and OS 17.3 vs. 44.3 months, p = 0.009, for treated vs untreated patients). The multivariate analysis confirmed the prognostic role of lymph node involvement and administration of adjuvant chemotherapy both on DFS (p = 0.018) and OS (p = 0.004). Conclusions: Our results confirm that node positivity is a major prognostic factor for invasive carcinomas derives from IPMNs and that these tumors may have a dismal prognosis. The role of adjuvant treatment for these patients seems promising but should be prospectively investigated. No significant financial relationships to disclose.
DISECCIÓN SUBMUCOSA ENDOSCÓPICA: RESULTADOS Y CURVA DE APRENDIZAJE DE UNA SERIE PROSPECTIVA DE 136 CASOS EN DOS CENTROS
Authors: M López Gómez, M Hernández Conde, J Santiago, C González Lois, P Matallanos, E Blázquez, JC Fernández Rial, JL Calleja Panero, L Abreu García, A Herreros De Tejada
Journal: Endoscopy (2016)

Introducción: La disección submucosa endoscópica (DSE) es una de las técnicas de elección para la resección en bloque de neoplasias gastrointestinales precoces (NGIP).
KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure
Authors: David T Yeung, Ljiljana Vidovic, Carine Tang, Deborah L White, Susan Branford, Timothy P Hughes, Agnes S.M. Yong
Journal: Blood (2014)
TCT-52 Proportion and Morphological Features of Restenosis Lesions with Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization after Sirolimus-Eluting Stent Implantation
Authors: Shunsuke Kubo, Akimune Kuwayama, Takenobu Shimada, Katsuya Miura, Masanobu Ohya, Hidewo Amano, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazushige Kadota
Journal: Journal of the American College of Cardiology (2016)
Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial
Authors: S. Giraudi, M. Lambertini, P. Anserini, F. Poggio, G. Iacono, A. Abate, S. Pastorino, A. Levaggi, A. D'Alonzo, M. Vaglica, G. Rossi, E. Blondeaux, F. Sozzi, C. Bighin, L. Miglietta, P. Pronzato, L. Del Mastro
Journal: Annals of Oncology (2015)
Targeting Cancer at the Nuclear Pore
Authors: Asfar S. Azmi, Ramzi M. Mohammad
Journal: Journal of Clinical Oncology (2016)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. February 29, 2016 ARTICLE CITATION DOI: 10.1200/JCO.2016.67.5637 Journal of Clinical Oncology - published online before print October 26, 2016 PMID: 27863200 Targeting Cancer at the Nuclear Pore Asfar S. AzmixAsfar S. AzmiSearch for articles by this author and Ramzi M. MohammadxRamzi M. MohammadSearch for articles by this author Show More Asfar S. Azmi and Ramzi M. Mohammad, Wayne State University School of Medicine, Detroit, MI https://doi.org/10.1200/JCO.2016.67.5637 First Page Full Text PDF Figures and Tables © 2016 by American Society of Clinical Oncology Companion First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
TCT-422 6 year clinical outcomes after Absorb bioresorbable scaffold implantation in small vessel: The Maasstad Absorb Registry
Authors: Valeria Paradies, Pieter Smits, Kees-Jan Royaards, Floris Kauer, Jochem Wassing, Martin van der Ent, George Vlachojannis
Journal: Journal of the American College of Cardiology (2016)